This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

26 Jul 2011

Teva Multiple Sclerosis Treatment Faces Generic Competition

Teva, the world's largest maker of generic drugs, is facing competition from generic versions.

Israel-based Teva Pharmaceutical, the maker of the multiple sclerosis drug Copaxone, is being dealt a taste of its own medicine, as its Copaxone faces competition from a generic copy.


Copazone generated more than $3bn of sales last year. But now Mylan and Momenta Pharmaceuticals have both requested USFDA approval to sell copies ahead of patent expiries due to occur in 2014 and 2015.


Both companies are questioning the validity of the patents, a strategy used religiously by Teva, while the generic company has launched cases against Mylan and Momenta citing patent infringement, a tactic used against Teva by Big Pharma.


Teva has also requested that the U

Related News